Literature DB >> 16973750

Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Hui Gao1, Xuesong Ouyang, Whitney A Banach-Petrosky, William L Gerald, Michael M Shen, Cory Abate-Shen.   

Abstract

Androgen independence is responsible for most prostate cancer lethality, yet currently there are no effective clinical treatments. We have been investigating the mechanisms underlying androgen-independent prostate cancer in Nkx3.1;Pten mutant mice, which display salient features of the disease, including a requirement for wild-type androgen receptor (AR) signaling. We now demonstrate that the Akt and Erk MAP kinase signaling pathways are activated in androgen-independent lesions of these mice. Forced activation of either Akt or Erk signaling in an androgen-responsive prostate cancer cell line promotes hormone-independent but AR-dependent growth in culture. Although these pathways act additively in culture, they act synergistically in vivo to promote tumorigenicity and androgen independence in the context of the prostate microenvironment. We propose that androgen independence emerges by means of epithelial-stromal competition, in which activation of Akt and Erk promotes AR activity in the prostate epithelium while counteracting antagonistic effects of the stroma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973750      PMCID: PMC1599986          DOI: 10.1073/pnas.0606836103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  The current state of hormonal therapy for prostate cancer.

Authors:  Beth A Hellerstedt; Kenneth J Pienta
Journal:  CA Cancer J Clin       Date:  2002 May-Jun       Impact factor: 508.702

Review 2.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.

Authors:  J T Arnold; J T Isaacs
Journal:  Endocr Relat Cancer       Date:  2002-03       Impact factor: 5.678

3.  Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.

Authors:  Minjung J Kim; Rajula Bhatia-Gaur; Whitney A Banach-Petrosky; Nishita Desai; Yuzhuo Wang; Simon W Hayward; Gerald R Cunha; Robert D Cardiff; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.

Authors:  C P Paweletz; L Charboneau; V E Bichsel; N L Simone; T Chen; J W Gillespie; M R Emmert-Buck; M J Roth; E F Petricoin III; L A Liotta
Journal:  Oncogene       Date:  2001-04-12       Impact factor: 9.867

Review 5.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Authors:  M Stanbrough; I Leav; P W Kwan; G J Bubley; S P Balk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

7.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

Authors:  Minjung J Kim; Robert D Cardiff; Nishita Desai; Whitney A Banach-Petrosky; Ramon Parsons; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

8.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Authors:  Shazli N Malik; Michael Brattain; Paramita M Ghosh; Dean A Troyer; Thomas Prihoda; Roble Bedolla; Jeffrey I Kreisberg
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

Review 9.  Chromosomal deletions and tumor suppressor genes in prostate cancer.

Authors:  J T Dong
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  71 in total

1.  Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression.

Authors:  Jiann-Jyh Lai; Kuo-Pao Lai; Kuang-Hsiang Chuang; Philip Chang; I-Chen Yu; Wen-Jye Lin; Chawnshang Chang
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

2.  Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.

Authors:  Yundong He; Ji Lu; Zhenqing Ye; Siyuan Hao; Liewei Wang; Manish Kohli; Donald J Tindall; Benyi Li; Runzhi Zhu; Liguo Wang; Haojie Huang
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

3.  Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Authors:  Shidong Jia; Xueliang Gao; Sang Hyun Lee; Sauveur-Michel Maira; Xiaoqiu Wu; Edward C Stack; Sabina Signoretti; Massimo Loda; Jean J Zhao; Thomas M Roberts
Journal:  Cancer Discov       Date:  2012-12-20       Impact factor: 39.397

Review 4.  Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.

Authors:  Vaqar Mustafa Adhami; Deeba Nadeem Syed; Naghma Khan; Hasan Mukhtar
Journal:  Biochem Pharmacol       Date:  2012-07-25       Impact factor: 5.858

5.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

Review 6.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

7.  Transcriptional activity of c-Jun is critical for the suppression of AR function.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

8.  Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Authors:  Nima Sharifi; Elaine M Hurt; Suneetha B Thomas; William L Farrar
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 9.  Targeting the androgen receptor pathway in prostate cancer.

Authors:  Yu Chen; Charles L Sawyers; Howard I Scher
Journal:  Curr Opin Pharmacol       Date:  2008-08-12       Impact factor: 5.547

10.  Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.

Authors:  Ryan Tasseff; Satyaprakash Nayak; Saniya Salim; Poorvi Kaushik; Noreen Rizvi; Jeffrey D Varner
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.